This study assessed the safety and efficacy of an mRNA rabies vaccine (LVRNA001) in dogs, mice, and cynomolgus macaques. LVRNA001, encoding the rabies virus glycoprotein, provided complete protection in dogs against both pre- and post-exposure infection. In mice, it protected against various rabies virus strains. Chronic toxicity studies in cynomolgus macaques and reproductive toxicity studies in rats revealed no significant adverse effects. LVRNA001 induced strong neutralizing antibody and Th1-biased immune responses in macaques. The results suggest LVRNA001 is a safe and promising rabies vaccine candidate.
Publisher
npj Vaccines
Published On
Jul 20, 2024
Authors
Jianglong Li, Pengcheng Yu, Qi Liu, Long Xu, Yan Chen, Yan Li, Fan Zhang, Wuyang Zhu, Yucai Peng
Tags
mRNA vaccine
rabies
canine protection
neutralizing antibodies
chronic toxicity
immune response
safety
Related Publications
Explore these studies to deepen your understanding of the subject.